These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20043031)

  • 21. Rare diseases, orphan drugs and their regulation: questions and misconceptions.
    Tambuyzer E
    Nat Rev Drug Discov; 2010 Dec; 9(12):921-9. PubMed ID: 21060315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What Is the Purpose of the Orphan Drug Act?
    Herder M
    PLoS Med; 2017 Jan; 14(1):e1002191. PubMed ID: 28045908
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 1992 Le Tourneau Award. Problems with pharmaceutical regulation in the United States. Drug lag and orphan drugs.
    Henry V
    J Leg Med; 1993 Dec; 14(4):617-39. PubMed ID: 8308452
    [No Abstract]   [Full Text] [Related]  

  • 24. Expansion of the Priority Review Voucher Program Under the 21
    Sinha MS; Jain N; Hwang T; Kesselheim AS
    Am J Law Med; 2018 May; 44(2-3):329-341. PubMed ID: 30106661
    [No Abstract]   [Full Text] [Related]  

  • 25. Pediatric testing of prescription drugs: the Food and Drug Administration's carrot and stick for the pharmaceutical industry.
    Karst KR
    Am Univ Law Rev; 2000; 49():739-72. PubMed ID: 11067732
    [No Abstract]   [Full Text] [Related]  

  • 26. New products highlight ambiguity of orphan drug law.
    Reid B
    Nat Biotechnol; 2003 Jan; 21(1):6-7. PubMed ID: 12511896
    [No Abstract]   [Full Text] [Related]  

  • 27. Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?
    Brabers AE; Moors EH; van Weely S; de Vrueh RL
    Orphanet J Rare Dis; 2011 Sep; 6():59. PubMed ID: 21892964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
    Burke KA; Freeman SN; Imoisili MA; Coté TR
    Clin Pharmacol Ther; 2010 Oct; 88(4):449-53. PubMed ID: 20856241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New drugs carry hefty price tags. Makers of leading-edge orphan products asked to cut prices, take smaller profits.
    Lee J
    Mod Healthc; 2013 Oct; 43(40):14. PubMed ID: 24340725
    [No Abstract]   [Full Text] [Related]  

  • 30. Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage.
    Kesselheim AS; Treasure CL; Joffe S
    PLoS Med; 2017 Jan; 14(1):e1002190. PubMed ID: 28045970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prescription for the Orphan Drug Act: the impact of the FDA's 1992 regulations and the latest congressional proposals for reform.
    Clissold DB
    Food Drug Law J; 1995; 50(1):125-47. PubMed ID: 10342989
    [No Abstract]   [Full Text] [Related]  

  • 32. Evaluation of orphan products by the U.S. Food and Drug Administration.
    Haffner ME; Kelsey JV
    Int J Technol Assess Health Care; 1992; 8(4):647-57. PubMed ID: 1464485
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Market watch: Upcoming market catalysts in Q1 2018.
    Collins T
    Nat Rev Drug Discov; 2018 Dec; 17(1):8-9. PubMed ID: 29282372
    [No Abstract]   [Full Text] [Related]  

  • 35. Characteristics of orphan drug applications that fail to achieve marketing approval in the USA.
    Heemstra HE; Leufkens HG; Rodgers RP; Xu K; Voordouw BC; Braun MM
    Drug Discov Today; 2011 Jan; 16(1-2):73-80. PubMed ID: 21094692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Orphan drugs.
    Novack GD
    Ocul Surf; 2008 Jan; 6(1):52-3. PubMed ID: 18264655
    [No Abstract]   [Full Text] [Related]  

  • 37. Developing drugs for developing countries.
    Ridley DB; Grabowski HG; Moe JL
    Health Aff (Millwood); 2006; 25(2):313-24. PubMed ID: 16522573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What makes an orphan drug?
    Hawkes N; Cohen D
    BMJ; 2010 Nov; 341():c6459. PubMed ID: 21081607
    [No Abstract]   [Full Text] [Related]  

  • 39. Lucrative niches: how drugs for rare diseases became lifeline for companies.
    Anand G
    Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
    [No Abstract]   [Full Text] [Related]  

  • 40. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years.
    Braun MM; Farag-El-Massah S; Xu K; Coté TR
    Nat Rev Drug Discov; 2010 Jul; 9(7):519-22. PubMed ID: 20531273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.